Abstract:Background: Receptor tyrosine kinases (RTKs) are potent oncoproteins in cancer that, when mutated or overexpressed, can cause uncontrolled growth of cells, angiogenesis, and metastasis, making them significant targets for cancer treatment. Vascular endothelial growth factor receptor 2 (VEGFR2), is a tyrosine kinase receptor that is produced in endothelial cells and is the most crucial regulator of angiogenic factors involved in tumor angiogenesis. So, a series of new substituted N-(4-((2-aminopyrimidin-5-yl)oxy)phenyl)-N-phenyl cyclopropane1,1-dicarboxamide derivatives as VEGFR-2 inhibitors have been designed and synthesized. Background: Receptor tyrosine kinases (RTKs) are potent oncoproteins in cancer that, when mutated or overexpressed, can cause uncontrolled growth of cells, angiogenesis, and metastasis, making them significant targets for cancer treatment. Vascular endothelial growth factor receptor 2 (VEGFR2), is a tyrosine kinase receptor that is produced in endothelial cells and is the most crucial regulator of angiogenic factors involved in tumor angiogenesis. So, a series of new substituted N-(4-((2-aminopyrimidin-5-yl)oxy)phenyl)-N-phenyl cyclopropane1,1-dicarboxamide derivatives as VEGFR-2 inhibitors have been designed and synthesized. Methods: Utilizing H-NMR, C13-NMR, and mass spectroscopy, the proposed derivatives were produced and assessed. HT-29 and COLO-205 cell lines were used for the cytotoxicity tests. The effective compound was investigated further for the Vegfr-2 kinase inhibition assay, cell cycle arrest, and apoptosis. A molecular docking examination was also carried out with the Maestro-12.5v of Schrodinger. Results: In comparison to the reference drug Cabozantinib (IC50 = 9.10 and 10.66 μM), compound SP2 revealed promising cytotoxic activity (IC50 = 4.07 and 4.98 μM) against HT-29 and COLO-205, respectively. The synthesized compound SP2 showed VEGFR-2 kinase inhibition activity with (IC50 = 6.82 μM) against the reference drug, Cabozantinib (IC50 = 0.045 μM). Moreover, compound SP2 strongly induced apoptosis by arresting the cell cycle in the G1 phase. The new compounds' potent VEGFR-2 inhibitory effect was noted with key amino acids Asp1044, and Glu883, and the hydrophobic interaction was also observed in the pocket of the VEGFR-2 active site by using a docking study. Conclusion: The results demonstrate that at the cellular and enzyme levels, the synthetic compounds SP2 are similarly effective as cabozantinib. The cell cycle and apoptosis data demonstrate the effectiveness of the suggested compounds. Based on the findings of docking studies, cytotoxic effects, in vitro VEGFR-2 inhibition, apoptosis, and cell cycle arrest, this research has given us identical or more effective VEGFR-2 inhibitors.

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.

Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors

Discovery of Biphenyl-Aryl Ureas As Novel VEGFR-2 Inhibitors. Part 4: Exploration of Diverse Hinge-Binding Fragments

Discovery of Novel VEGFR-2 Inhibitors. Part 5: Exploration of Diverse Hinge-Binding Fragments Via Core-Refining Approach

Design, Synthesis, Biological Evaluation of Benzoyl Amide Derivatives Containing Nitrogen Heterocyclic Ring As Potential VEGFR-2 Inhibitors

Biphenyl Derivatives Incorporating Urea Unit As Novel Vegfr-2 Inhibitors: Design, Synthesis and Biological Evaluation

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Design, Synthesis and Biological Evaluation of Pyrimidine-Based Derivatives As VEGFR-2 Tyrosine Kinase Inhibitors.

Discovery of novel VEGFR-2 inhibitors. Part II: Biphenyl urea incorporated with salicylaldoxime

Discovery of New 4‐alkoxyquinazoline‐based Derivatives As Potent VEGFR2 Inhibitors

Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine Derivatives As Novel VEGFR-2 Kinase Inhibitors.

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazo-line and diarylamide fragments

Discovery of Novel Anti-Angiogenesis Agents. Part 7: Multitarget Inhibitors of VEGFR-2, TIE-2 and EphB4.

Design, Synthesis and in Vitro Evaluation of 6-Amide-2-aryl Benzoxazole/benzimidazole Derivatives Against Tumor Cells by Inhibiting VEGFR-2 Kinase.

Discovery of 1,3‐diaryl‐pyridones As Potent VEGFR‐2 Inhibitors: Design, Synthesis, and Biological Evaluation

Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.

Protein–ligand Interaction-Guided Discovery of Novel VEGFR-2 Inhibitors

Discovery of 4,6‐disubstituted Pyrimidine Derivatives As Novel Dual VEGFR2/FGFR1 Inhibitors

Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation

Discovery of Novel Picolinamide-Based Derivatives As Novel VEGFR-2 Kinase Inhibitors: Synthesis,in Vitrobiological Evaluation and Molecular Docking

Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-Cancer Studies